Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Phase:
Phase 2
Details
Lead Sponsor:
Galecto Biotech AB
Collaborator:
OPIS s.r.l